AAAAAA

   
Results: 1-8 |
Results: 8
STUDIES ON THE MOLECULAR MECHANISM OF GROWTH-INHIBITION WITH P53 ADENOVIRAL CONSTRUCT IN HUMAN OVARIAN-CANCER
Authors: MUJOO K CATINO JJ MANEVAL DC GUTTERMAN JU
Citation: K. Mujoo et al., STUDIES ON THE MOLECULAR MECHANISM OF GROWTH-INHIBITION WITH P53 ADENOVIRAL CONSTRUCT IN HUMAN OVARIAN-CANCER, International journal of gynecological cancer, 8(3), 1998, pp. 233-241
PHASE-IA IB TRIAL OF ANTI-GD2 CHIMERIC MONOCLONAL-ANTIBODY-14.18 (CH14.18) AND RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (RHGM-CSF) IN METASTATIC MELANOMA/
Authors: MURRAY JL KLEINERMAN ES JIA SF ROSENBLUM MG ETON O BUZAID A LEGHA S ROSS MI THOMPSON L MUJOO K RIEGER PT SALEH M KHAZAELI MB VADHANRAJ S
Citation: Jl. Murray et al., PHASE-IA IB TRIAL OF ANTI-GD2 CHIMERIC MONOCLONAL-ANTIBODY-14.18 (CH14.18) AND RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (RHGM-CSF) IN METASTATIC MELANOMA/, Journal of immunotherapy with emphasis on tumor immunology, 19(3), 1996, pp. 206-217
ADENOVIRAL-MEDIATED P53 TUMOR-SUPPRESSOR GENE-THERAPY OF HUMAN OVARIAN-CARCINOMA
Authors: MUJOO K MANEVAL DC ANDERSON SC GUTTERMAN JU
Citation: K. Mujoo et al., ADENOVIRAL-MEDIATED P53 TUMOR-SUPPRESSOR GENE-THERAPY OF HUMAN OVARIAN-CARCINOMA, Oncogene, 12(8), 1996, pp. 1617-1623
CELLULAR-RESISTANCE TO THE ANTIMELANOMA IMMUNOTOXIN ZME-GELONIN AND STRATEGIES TO TARGET RESISTANT CELLS
Authors: ROSENBLUM MG CHEUNG L KIM SK MUJOO K DONATO NJ MURRAY JL
Citation: Mg. Rosenblum et al., CELLULAR-RESISTANCE TO THE ANTIMELANOMA IMMUNOTOXIN ZME-GELONIN AND STRATEGIES TO TARGET RESISTANT CELLS, Cancer immunology and immunotherapy, 42(2), 1996, pp. 115-121
AN ANTIMELANOMA IMMUNOTOXIN CONTAINING RECOMBINANT HUMAN TUMOR-NECROSIS-FACTOR - TISSUE DISPOSITION, PHARMACOKINETIC, AND THERAPEUTIC STUDIES IN XENOGRAFT MODELS
Authors: ROSENBLUM MG CHEUNG L MUJOO K MURRAY JL
Citation: Mg. Rosenblum et al., AN ANTIMELANOMA IMMUNOTOXIN CONTAINING RECOMBINANT HUMAN TUMOR-NECROSIS-FACTOR - TISSUE DISPOSITION, PHARMACOKINETIC, AND THERAPEUTIC STUDIES IN XENOGRAFT MODELS, Cancer immunology and immunotherapy, 40(5), 1995, pp. 322-328
PHARMACOKINETICS, TISSUE DISTRIBUTION, AND IN-VIVO ANTITUMOR EFFECTS OF THE ANTIMELANOMA IMMUNOTOXIN ZME-GELONIN
Authors: MUJOO K CHEUNG L MURRAY JL ROSENBLUM MG
Citation: K. Mujoo et al., PHARMACOKINETICS, TISSUE DISTRIBUTION, AND IN-VIVO ANTITUMOR EFFECTS OF THE ANTIMELANOMA IMMUNOTOXIN ZME-GELONIN, Cancer immunology and immunotherapy, 40(5), 1995, pp. 339-345
EFFECT OF TUMOR-NECROSIS-FACTOR-ALPHA ON BIODISTRIBUTION OF AN ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR (EGFR) MONOCLONAL-ANTIBODY IN-VIVO
Authors: MURRAY JL WILMANNS C KILBOURN R MUJOO K KASI LP ZHANG HZ DONATO N ROSENBLUM MG
Citation: Jl. Murray et al., EFFECT OF TUMOR-NECROSIS-FACTOR-ALPHA ON BIODISTRIBUTION OF AN ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR (EGFR) MONOCLONAL-ANTIBODY IN-VIVO, Antibody immunoconjugates, and radiopharmaceuticals, 7(4), 1994, pp. 261-275
PHASE-I TRIAL OF MURINE MONOCLONAL-ANTIBODY 14G2 A ADMINISTERED BY PROLONGED INTRAVENOUS-INFUSION IN PATIENTS WITH NEUROECTODERMAL TUMORS
Authors: MURRAY JL CUNNINGHAM JE BREWER H MUJOO K ZUKIWSKI AA PODOLOFF DA KASI LP BHADKAMKAR V FRITSCHE HA BENJAMIN RS LEGHA SS ATER JL JAFFE N ITOH K ROSS MI BUCANA CD THOMPSON L CHEUNG L ROSENBLUM MG
Citation: Jl. Murray et al., PHASE-I TRIAL OF MURINE MONOCLONAL-ANTIBODY 14G2 A ADMINISTERED BY PROLONGED INTRAVENOUS-INFUSION IN PATIENTS WITH NEUROECTODERMAL TUMORS, Journal of clinical oncology, 12(1), 1994, pp. 184-193
Risultati: 1-8 |